T-cell Large Granular Lymphocytic Leukemia
Conditions
Keywords
T-cell Large Granular Lymphocytic Leukemia, T-LGLL
Brief summary
An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
Interventions
DRUGABC008
Given subcutaneous injection
Sponsors
Abcuro, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Is at least 18 years of age. * Has body mass index (BMI) ≤35 kg/m2. * Has a documented diagnosis of T LGLL. * Has any 1 or more of the following at Screening: * Absolute neutrophil count (ANC) \<0.5 x 109/L * ANC ≥0.5 x 109/L and \<1.0 x 109/L associated with recurrent infection (≥2 or more infections requiring antimicrobial therapy within the previous 12 months) * Hemoglobin (Hgb) \<8 g/dL or packed red blood cell transfusion frequency ≥1 time in the 4 weeks immediately prior to Screening * Hgb ≥8 g/dL and \<10 g/dL accompanied by documented symptoms of anemia, e.g., fatigue, weakness, pale or yellowish skin, irregular heartbeat, shortness of breath, dizziness, or lightheadedness. * Has adequate hepatic and renal function at Screening, as indicated by: * Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST); \<2.5x the upper limit of normal (ULN) * Total bilirubin ≤1.5 ULN; subjects with Gilbert syndrome must have a total bilirubin \<3.0x ULN with direct bilirubin \<1.0x ULN at time of Screening * Estimated glomerular filtration rate (eGFR) ≥45 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) equation corrected for the body surface area of the subject calculated by the Mosteller equation and divided by 1.73 * Agrees to adhere to the current Centers for Disease Control advice regarding minimizing exposure to severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) from the first Screening Visit until the End of Study (EOS)/Early Termination Visit (ETV).
Exclusion criteria
* Has reactive large granular lymphocytosis. * Has active anemia secondary to confirmed etiologies other than T-LGLL, including known vitamin or mineral deficiency, gastrointestinal bleeding, or genetic disorder; or has active neutropenia secondary to known vitamin or mineral deficiencies or genetic disorder. * Has a platelet count ≤20 x 109/L or other clinically significantly abnormal laboratory results not related to the underlying condition in the Investigator's or Sponsor's opinion at Screening. * Has known hypersensitivity to any component of the formulation of ABC008, or history of anaphylaxis to any prior mAb therapy. * Has any other autoimmune or autoinflammatory disease other than RA, inclusion body myositis (IBM), secondary Sjogren's syndrome (SS), or thyroid disease. * Has another myelo /lympho proliferative disorder or malignancy (other than monoclonal gammopathy of unknown significance \[MGUS\] not requiring treatment) within the past 5 years prior to Screening except completely resected nonmelanoma skin cancer, curatively treated localized prostate cancer, and completely resected carcinoma in situ at any site. * Has a current diagnosis of active tuberculosis (TB) * Has a history of herpes zoster infection that was disseminated, required hospitalization, or IV antiviral therapy in the 24 weeks prior to Day 1. * Active, chronic, or past history of hepatitis B virus or hepatitis C virus (HCV) infection (hepatitis B core antibody or surface antigen positive, or HCV antibody positive with reflex HCV ribonucleic acid \[RNA\] positive at Screening; individuals who have received curative therapy for HCV are permitted if therapy was completed at least 24 weeks prior to Screening and subject is HCV RNA negative); * Has known active bacterial, viral, fungal, or atypical mycobacterial infection, or any major episode of infection that required hospitalization * Has received live (including attenuated) vaccination in the 30 days prior to Day 1 or killed vaccine within 14 days prior to Day 1. * Is human immunodeficiency virus (HIV) positive by antigen/antibody test, human T cell lymphotropic virus (HTLV 1 or 2) positive by antibody test. * Has had major surgery (defined as surgery requiring general or regional anesthesia) within 6 weeks prior to Day 1 or is expected to receive surgery during the study. * Has a history of organ transplant (e.g., solid, bone marrow) or is expected to receive one during the study. * Has any other condition or social situations that would interfere with the subject's study participation, increase the risk associated with study participation or investigational product administration, interfere with the interpretation of study results, or would otherwise make the subject inappropriate for entry into this study in the Investigator's or Sponsor's opinion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence, nature, and severity of treatment-emergent AEs and SAEs as determined by NCI CTCAE v5.0 | Through Study Completion an average of 48 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in safety lab (Hematology) | Through Study Completion an average of 48 weeks | — |
| Change from baseline in safety lab (Chemistry) | Through Study Completion an average of 48 weeks | — |
| Change from baseline in safety lab (Coagulation) | Through Study Completion an average of 48 weeks | Includes the following coagulation labs: INR and aPTT |
| Change from baseline in safety lab (Complement) | Through Study Completion an average of 48 weeks | Includes the following complement labs: C3 and CH50 |
| Change from baseline in safety lab (Cytokines) | Through Study Completion an average of 48 weeks | — |
| Change from baseline in safety lab (CMV Viral Load) | Through Study Completion an average of 48 weeks | — |
| Change from baseline in safety lab (EBV Viral Load) | Through Study Completion an average of 48 weeks | — |
| Change from baseline in ECG (Rhythm) | Through Study Completion an average of 48 weeks | — |
| Change from baseline in ECG (Heart Rate) | Through Study Completion an average of 48 weeks | — |
| Change from baseline in ECG parameters | Through Study Completion an average of 48 weeks | Includes the following ECG parameters: RR interval, PR interval, QRS interval, QT interval, QT interval corrected by Bazett's formula, and QTcF |
| Change from baseline in vital sign (Systolic and diastolic blood pressure) | Through Study Completion an average of 48 weeks | — |
| Change from baseline in vital sign (temperature) | Through Study Completion an average of 48 weeks | — |
| Change from baseline in vital sign (respiratory rate) | Through Study Completion an average of 48 weeks | — |
| Change from baseline in vital sign (pulse rate) | Through Study Completion an average of 48 weeks | — |
| Percentage of subjects demonstrating overall response (defined as total number of subjects with CR or PR) at all time points assessed | Day 1 and throughout the 48 weeks of follow up | — |
| Percentage of subjects demonstrating complete response at all time points assessed | Day 1 and throughout the 48 weeks of follow up | A complete response is defined by normalization of hemoglobin, neutrophil and platelet levels without transfusion |
| Percentage of subjects demonstrating partial response at all time points assessed | Day 1 and throughout the 48 weeks of follow up | A partial response is defined by improvement in any of the following criteria but not all: hemoglobin, neutrophil and platelet levels without transfusion |
| Duration of response at all time points assessed | Day 1 and throughout the 48 weeks of follow up | — |
| Overall survival at Week 48 | Day 1 and throughout the 48 weeks of follow up | — |
| The change from baseline in levels of KLRG1 expressing lymphocytes over time | Day 1 and throughout the 48 weeks of follow up | — |
| The change from baseline in levels of T-LGL counts over time | Day 1 and throughout the 48 weeks of follow up | — |
| The change from baseline in levels of lymphocyte subsets over time | Day 1 and throughout the 48 weeks of follow up | — |
| The maximum serum concentration [CMax] of ABC008 | Day 1 and throughout the 48 weeks of follow up | — |
| The time to maximum concentration [TMax] of ABC008 | Day 1 and throughout the 48 weeks of follow up | — |
| The area under the concentration-time curve [AUC] of ABC008 | Day 1 and throughout the 48 weeks of follow up | — |
| The apparent clearance [CL/F] of ABC008 | Day 1 and throughout the 48 weeks of follow up | — |
| The apparent volume of distribution [Vd/F] of ABC008 | Day 1 and throughout the 48 weeks of follow up | — |
| The elimination half-life [t½] of ABC008 | Day 1 and throughout the 48 weeks of follow up | — |
Countries
United States
Outcome results
None listed